Windlas Biotech Limited has made a regulatory disclosure to the BSE and NSE pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company informed the exchanges that it experienced a cyber security incident on October 30, 2026. The disclosure explicitly states that this incident does not have any material impact on the company's core business operations, financial performance, or business continuity.
A detailed assessment of the incident is currently underway. The company is implementing appropriate remedial and preventive measures as required. The disclosure was characterized as being made as a matter of good governance.
The letter was signed by Ananta Narayan Panda, Company Secretary & Compliance Officer, on behalf of Windlas Biotech Limited.